Safety, ethical, and regulatory considerations in nanotechnology for skin cancer

The rising prevalence of skin cancer worldwide emphasizes the critical need for novel therapeutic and diagnostic approaches that go beyond conventional methods. Through improved drug delivery, targeted therapy, and sophisticated diagnostic applications, nanotechnology holds revolutionary promise in the field of oncology. The safety, ethical, and regulatory aspects of nanotechnology's multifaceted role in the treatment of skin cancer are highlighted in this chapter. Systemic toxicity is reduced by nanoparticles with enhanced biocompatibility, site-specific drug delivery, and imaging precision, such as liposomes, polymeric carriers, metallic nanostructures, and quantum dots. In spite of these developments, issues with biodistribution, long-term toxicity, and possible genotoxic effects still continue to impact nanomedicine. Informed consent, fair access, environmental sustainability, and data privacy are ethical factors to be taken into account in clinical applications and nanomedical research. ssAdditionally, regulatory frameworks are still evolving as international organizations like the FDA and EMA keep establishing guidelines for post-market surveillance, safety evaluation, and characterization. The chapter emphasizes the value of interdisciplinary cooperation in ensuring the responsible development, moral application, and thorough evaluation of nanotechnology-based interventions. Transforming nanotechnological advancements into safe and efficient treatments for patients with skin cancer requires the integration of safety testing, ethical consideration, and standardized international regulation.